Added to YB: 2026-08-04
Pitch date: 2026-08-01
LNTH [neutral]
Lantheus Holdings, Inc.
-1.43%
current return
Author Info
The Catholic Family Office shares investment insights and portfolio updates. Sign up for the newsletter.
Company Info
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Market Cap
$6.5B
Pitch Price
$102.66
Price Target
N/A
Dividend
N/A
EV/EBITDA
17.76
P/E
23.94
EV/Sales
4.28
Sector
Health Care Equipment and Supplies
Category
growth
Company a Day #12: Lantheus Holdings
LNTH (overview): Radiopharma orchestrator refocused on PET diagnostics. Flagship PYLARIFY (PSMA prostate PET), DEFINITY (cardiac ultrasound), Neuraceq (Alzheimer's amyloid). Sold SPECT to SHINE; added LMI & Evergreen CDMO in 2025. TruVu launch Q4 '26. Risks: LNTH-2501 CRL, franchise concentration, decay-driven ops, generic/reimbursement pressure, integration.
Read full article (18 min)